In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer

Takashi Endo, Masahiro Toda, Masahiko Watanabe, Yukihiko Iizuka, Tetsuro Kubota, Masaki Kitajima, Yutaka Kawakami

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 tumor tissue was transplanted onto the wall of the cecum and G207 was injected in the established cecum tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intratumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intratumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intratumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves tumor-specific T-cell responses.

Original languageEnglish
Pages (from-to)142-148
Number of pages7
JournalCancer Gene Therapy
Volume9
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Colonic Neoplasms
Vaccination
Neoplasm Metastasis
Liver
Neoplasms
Cecum
Subcutaneous Injections
Colon
Therapeutics
Carcinoma
Cancer Vaccines
Injections
Cytotoxic T-Lymphocytes
Therapeutic Uses
Nude Mice
T-Lymphocytes

Keywords

  • Colon cancer
  • G207
  • Gene therapy
  • HSV
  • Immunotherapy
  • Liver metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. / Endo, Takashi; Toda, Masahiro; Watanabe, Masahiko; Iizuka, Yukihiko; Kubota, Tetsuro; Kitajima, Masaki; Kawakami, Yutaka.

In: Cancer Gene Therapy, Vol. 9, No. 2, 2002, p. 142-148.

Research output: Contribution to journalArticle

Endo, Takashi ; Toda, Masahiro ; Watanabe, Masahiko ; Iizuka, Yukihiko ; Kubota, Tetsuro ; Kitajima, Masaki ; Kawakami, Yutaka. / In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. In: Cancer Gene Therapy. 2002 ; Vol. 9, No. 2. pp. 142-148.
@article{9ed1f6f63167404b95dc3af4772c83ed,
title = "In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer",
abstract = "In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 tumor tissue was transplanted onto the wall of the cecum and G207 was injected in the established cecum tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intratumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intratumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intratumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves tumor-specific T-cell responses.",
keywords = "Colon cancer, G207, Gene therapy, HSV, Immunotherapy, Liver metastasis",
author = "Takashi Endo and Masahiro Toda and Masahiko Watanabe and Yukihiko Iizuka and Tetsuro Kubota and Masaki Kitajima and Yutaka Kawakami",
year = "2002",
doi = "10.1038/sj/cgt/7700407",
language = "English",
volume = "9",
pages = "142--148",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer

AU - Endo, Takashi

AU - Toda, Masahiro

AU - Watanabe, Masahiko

AU - Iizuka, Yukihiko

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

AU - Kawakami, Yutaka

PY - 2002

Y1 - 2002

N2 - In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 tumor tissue was transplanted onto the wall of the cecum and G207 was injected in the established cecum tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intratumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intratumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intratumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves tumor-specific T-cell responses.

AB - In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 tumor tissue was transplanted onto the wall of the cecum and G207 was injected in the established cecum tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intratumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intratumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intratumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves tumor-specific T-cell responses.

KW - Colon cancer

KW - G207

KW - Gene therapy

KW - HSV

KW - Immunotherapy

KW - Liver metastasis

UR - http://www.scopus.com/inward/record.url?scp=0036167471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036167471&partnerID=8YFLogxK

U2 - 10.1038/sj/cgt/7700407

DO - 10.1038/sj/cgt/7700407

M3 - Article

VL - 9

SP - 142

EP - 148

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 2

ER -